Unlock instant, AI-driven research and patent intelligence for your innovation.

Screening method of vGPCR protein targeting peptide, chimeric toxin and application thereof

A screening method and protein target technology, applied in the field of vGPCR protein targeting peptide screening, can solve problems such as poor prognosis and no optimal treatment plan

Pending Publication Date: 2021-12-07
SHANGHAI JIAO TONG UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Kaposi's sarcoma virus (Kaposi , s sarcoma associated herpesvirus, KSHV), also known as human herpesvirus type 8 (HHV-8), the tumors caused by KSHV account for about 2% of the total number of tumors related to pathogenic infection in the world, and the types of tumors induced by it include Kappo Kaposi's Sarcoma (KS), Primary Effusion Lymphoma (PEL) and Multicentric Castleman's disease (MCD), etc. PEL currently has no optimal treatment plan and the prognosis is very poor. The average survival time is only about 6 months; KS is one of the main causes of death in AIDS patients when the HIV titer is under control

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening method of vGPCR protein targeting peptide, chimeric toxin and application thereof
  • Screening method of vGPCR protein targeting peptide, chimeric toxin and application thereof
  • Screening method of vGPCR protein targeting peptide, chimeric toxin and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Screening of short peptides specifically binding to vGPCR proteins

[0028] The specific operation is as follows:

[0029] 1. Lentiviral packaging and stable cell line construction

[0030] 1. Plasmid construction: vGPCR and GFP were inserted into the pLVX IRES Puro vector with EcoRI / XbaI and XbaI / NotI. After successful sequencing, STBL3 was used to amplify, and VSVG and pSPAX were simultaneously amplified and plasmids were extracted.

[0031] 2. Cell plating: Inoculate HEK293T on a 10cm dish, and grow the cell density to 60-70%.

[0032] 3. Lentiviral packaging:

[0033] 1) Measure 1.25 μg of VSVG, 3.5 μg of pSPAX2 and 5 μg of recombinant plasmid into 500 μL of blood-free and anti-antibody-free DMEM medium, add 30 μL of PEI, mix thoroughly and let stand for 20 minutes.

[0034] 2) After 6 hours of transfection, replace with complete medium, and collect the supernatant at 24, 48, and 72 hours.

[0035] 4. Lentivirus purification: centrifuge at 4000rpm for...

Embodiment 2

[0084] Example 2: Using immunofluorescence to verify the affinity of vGPCR proteins and candidate short peptides

[0085] The specific operation is as follows:

[0086] 1. Short peptide synthesis: Coupling the N-terminal of the candidate polypeptide fragments corresponding to the three positive clones (1C3, 1F10, 1B5) with strong vGPCR binding ability in the figure to biotin (1C3: Biotin-LR; 1F10: Biotin- FL; 1B5: Biotin-SR), this part was completed by Shanghai Gill Biological Co., Ltd.

[0087] 2. Cell plating: Put the cell slides into a 6-well plate, wash with ice PBS three times, seed GFP / HEK293T and vGPCR-GFP / HEK293T cells in a 6-well plate overnight, and the cell density reaches 60-70%;

[0088] 3. Fix the cells: Aspirate the culture medium, wash twice with ice-cold PBS, fix with 4% paraformaldehyde at room temperature for 30 min.

[0089] 4. Blocking: After washing with PBS three times, add 0.2% FSG blocking solution, and block at room temperature for 0.5 h.

[0090] ...

Embodiment 3

[0095] Example 3: Specific killing activity of chimeric toxin FL-Lytic on KSHV-related tumor cells

[0096] The specific operation is as follows:

[0097] 1. Short peptide synthesis: Synthesis of chimeric toxin (FL-Lytic) and cleavage peptide (Lytic) as a negative control, this part was completed by Shanghai Qiangyao Biotechnology Co., Ltd.

[0098] FL-Lytic:FGDRTITQMSQLGGGKLLLKLLKKLLKLLKKK

[0099] Lytic: KLLLKLLKKLLKLLKKK

[0100] 2. Cell killing activity test: 25,000 KSHV-related tumor cells (BCBL-1, BCP-1 are KSHV-positive cells, BJAB and DG75 are KSHV-negative cells) were planted in 96-well plates (25,000 / 50 μL containing 10% FBS 1640 medium), then add 50 μL of different concentrations of chimeric toxin solutions (0, 2.5, 5, 10 μmol / L) prepared in 1640 medium with 10% FBS, and treat at 37 ° C for 2 h under the condition of 5%. Cell viability was detected by MTT reagent.

[0101] The result is as Figure 4 As shown, it was found that for KSHV-positive cells, the chime...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a screening method of a vGPCR protein targeting peptide, chimeric toxin derived from the vGPCR protein targeting peptide and application, and relates to the technical field of biological medicine. The screening method of the targeting peptide comprises of lentivirus packaging and stable cell line construction; and alternately carrying out bacteriophage screening, purification and combination of His-vGPCR and vGPCR1-51-Fc proteins, and screening of monoclonal candidate bacteriophages of vGPCR protein oligopeptides by utilizing cell lines which express and do not express vGPCR proteins. A chimeric toxin molecule constructed based on the targeting peptide can effectively and selectively kill KSHV related tumor cells and inhibit tumor progression, and can be further developed into an anti-tumor drug, meanwhile, the targeting short peptide can also be transformed to be used as a reagent of indirect enzyme-linked immunosorbent assay, immunoblotting, immunohistochemistry and other detection methods taking vGPCR as a target spot, and the method is applied to fundamental research and clinical diagnosis and treatment.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a screening method for a vGPCR protein targeting peptide, a chimeric toxin and its application. Background technique [0002] Kaposi's sarcoma virus (Kaposi , s sarcoma associated herpesvirus, KSHV), also known as human herpesvirus type 8 (HHV-8), the tumors caused by KSHV account for about 2% of the total number of tumors related to pathogenic infection in the world, and the types of tumors induced by it include Kappo Kaposi's Sarcoma (KS), Primary Effusion Lymphoma (PEL) and Multicentric Castleman's disease (MCD), etc. PEL currently has no optimal treatment plan and the prognosis is very poor. The average survival time is only about 6 months; KS is one of the main causes of death of AIDS patients when the HIV titer is under control. [0003] There are two stages of infection in the KSHV life cycle, the latent period and the cleavage replication period. The viral G protein...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C12N15/12C12N15/867C12N5/10A61K47/64A61K47/54A61K38/16A61P35/00A61P31/22G01N33/68G01N33/574
CPCC07K7/08C07K14/705C12N15/86A61K47/64A61K47/54A61K38/16A61P35/00A61P31/22G01N33/6893G01N33/57484C12N2740/15043G01N2333/705
Inventor 魏芳郑响蔡启良丁玲
Owner SHANGHAI JIAO TONG UNIV